{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:43:56Z","timestamp":1785905036687,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United Kingdom Research and Innovation Medical Research Council","award":["MC_UU_00002\/11"],"award-info":[{"award-number":["MC_UU_00002\/11"]}]},{"name":"United Kingdom Research and Innovation Medical Research Council","award":["MC_UU_00002\/10"],"award-info":[{"award-number":["MC_UU_00002\/10"]}]},{"name":"Department of Health and Social Care National Institute for Health Research","award":["MC_PC_19074"],"award-info":[{"award-number":["MC_PC_19074"]}]},{"name":"NIHR Health Protection Unit in Behavioural Science and Evaluation"},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR\u2005=\u20050.85; 95% confidence interval [CI], .77\u2013.94), hospital admission or emergency care attendance (aHR\u2005=\u20050.87; 95% CI, .81\u2013.94), and COVID-19 mortality (aHR\u2005=\u20050.85; 95% CI, .71\u20131.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.<\/jats:p>","DOI":"10.1093\/infdis\/jiac063","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T20:10:37Z","timestamp":1645042237000},"page":"808-811","source":"Crossref","is-referenced-by-count":8,"title":["Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-0626","authenticated-orcid":false,"given":"Tommy","family":"Nyberg","sequence":"first","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1387-0200","authenticated-orcid":false,"given":"Katie","family":"Harman","sequence":"additional","affiliation":[{"name":"COVID-19 National Epidemiology Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-2539","authenticated-orcid":false,"given":"Asad","family":"Zaidi","sequence":"additional","affiliation":[{"name":"COVID-19 National Epidemiology Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-5937","authenticated-orcid":false,"given":"Shaun R","family":"Seaman","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2684","authenticated-orcid":false,"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Immunisation and Countermeasures Division, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-6982","authenticated-orcid":false,"given":"Sophie G","family":"Nash","sequence":"additional","affiliation":[{"name":"COVID-19 National Epidemiology Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-0432","authenticated-orcid":false,"given":"Andre","family":"Charlett","sequence":"additional","affiliation":[{"name":"National Infection Service, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-5653","authenticated-orcid":false,"given":"Jamie","family":"Lopez Bernal","sequence":"additional","affiliation":[{"name":"Immunisation and Countermeasures Division, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-1164","authenticated-orcid":false,"given":"Richard","family":"Myers","sequence":"additional","affiliation":[{"name":"Genomics Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-3484","authenticated-orcid":false,"given":"Natalie","family":"Groves","sequence":"additional","affiliation":[{"name":"Genomics Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Genomics Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0206-051X","authenticated-orcid":false,"given":"Saheer","family":"Gharbia","sequence":"additional","affiliation":[{"name":"Genomics Programme, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-0340","authenticated-orcid":false,"given":"Meera","family":"Chand","sequence":"additional","affiliation":[{"name":"Genomics Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-2724","authenticated-orcid":false,"given":"Simon","family":"Thelwall","sequence":"additional","affiliation":[{"name":"COVID-19 National Epidemiology Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-6112","authenticated-orcid":false,"given":"Daniela","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-5945","authenticated-orcid":false,"given":"Gavin","family":"Dabrera","sequence":"additional","affiliation":[{"name":"COVID-19 National Epidemiology Cell, UK Health Security Agency , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-4427","authenticated-orcid":false,"given":"Anne M","family":"Presanis","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"2022091319143647900_CIT0001","author":"UK Health Security Agency."},{"key":"2022091319143647900_CIT0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.","volume":"22","author":"Twohig","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2022091319143647900_CIT0003","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.13.21262014","article-title":"Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic.","author":"Seaman","year":"18","journal-title":"medRxiv"},{"key":"2022091319143647900_CIT0004","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267806","article-title":"REACT-1 round 15 final report: increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection.","author":"Chadeau-Hyam","year":"16","journal-title":"medRxiv"},{"key":"2022091319143647900_CIT0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"key":"2022091319143647900_CIT0006","doi-asserted-by":"crossref","first-page":"n1412","DOI":"10.1136\/bmj.n1412","article-title":"Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis.","volume":"373","author":"Nyberg","year":"2021","journal-title":"BMJ"},{"key":"2022091319143647900_CIT0007","doi-asserted-by":"crossref","first-page":"2100348","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021.","volume":"26","author":"Funk","year":"2021","journal-title":"Euro Surveill"},{"key":"2022091319143647900_CIT0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"2022091319143647900_CIT0009","doi-asserted-by":"crossref","first-page":"2100509","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509","article-title":"Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.","volume":"26","author":"Campbell","year":"2021","journal-title":"Euro Surveill"},{"key":"2022091319143647900_CIT0010","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"2022091319143647900_CIT0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant.","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"2022091319143647900_CIT0012","doi-asserted-by":"crossref","first-page":"E1619","DOI":"10.1503\/cmaj.211248","article-title":"Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada.","volume":"193","author":"Fisman","year":"2021","journal-title":"CMAJ"},{"key":"2022091319143647900_CIT0013","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.17.21267925","article-title":"SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of delta sub-lineages and increased transmissibility of AY.4.2.","author":"Eales","year":"17","journal-title":"medRxiv"},{"key":"2022091319143647900_CIT0014","doi-asserted-by":"crossref","first-page":"2101059","DOI":"10.2807\/1560-7917.ES.2021.26.49.2101059","article-title":"Neutralisation of the SARS-CoV-2 delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.","volume":"26","author":"Lassauni\u00e8re","year":"2021","journal-title":"Euro Surveill"},{"key":"2022091319143647900_CIT0015","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4025932","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England.","author":"Nyberg","year":"4","journal-title":"SSRN"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac063\/42843082\/jiac063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/5\/808\/45819803\/jiac063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/5\/808\/45819803\/jiac063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T19:15:08Z","timestamp":1663096508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/5\/808\/6532623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,20]]},"published-print":{"date-parts":[[2022,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac063","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,2,20]]}}}